Targets › HEXB
2 programs from 2 companies in 2 trials: 2 Phase 1; Metabolic and endocrine, Neurology; next expected readout Jan 2027.
Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the oligosaccharide moieties from proteins and neutral glycolipids, or from certain mucopolysaccharides. The isozyme B does not hydrolyze each of these substrates, however hydrolyzes efficiently neutral oligosaccharide. (UniProt, P07686)
Open in Phaseline: the race on HEXB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Peter Ljubenkov, MD | Verdiperstat Hexosaminidase B (HEXB) inhibitor | HEXB | Phase 1 | Semantic Dementia | Jan 2027 |
| Dr. Anupam Sehgal | TSHA-101 AAV9 viral vector containing HEXA and HEXB genes | HEXA, HEXB | Phase 1 | Infantile GM2 Gangliosidosis (Disorder) | Mar 2027 |
Infantile GM2 Gangliosidosis (Disorder) (1) Semantic Dementia (1)
protein or peptide (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.